Reuters logo
BRIEF-Axsome therapeutics receives FDA clearance of IND for Phase 2/3 trial of AXS-05
January 3, 2017 / 1:16 PM / in 10 months

BRIEF-Axsome therapeutics receives FDA clearance of IND for Phase 2/3 trial of AXS-05

Jan 3 (Reuters) - Axsome Therapeutics Inc :

* Axsome therapeutics receives FDA clearance of ind for phase 2/3 trial of axs-05 in alzheimer’s disease agitation

* Axsome Therapeutics Inc - axsome anticipates commencing this trial in first half of 2017. Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below